Sanofi ADS (SNY) Financial Statements

Sanofi ADS

SNY · NASDAQ-GS

No income data available for this period yet.

Analyst Estimates

Period	Consensus EPS	Low	High	Estimates	Revisions
Dec 2026	$4.96	$4.83	$5.10	7	↑1 ↓0
Dec 2027	$5.18	$4.62	$5.45	7	↑0 ↓1
Dec 2028	$5.49	$4.86	$5.84	3	↑0 ↓0
Dec 2029	$5.28	$5.28	$5.28	1	↑0 ↓0

Forward estimates are the sell-side consensus reported by Nasdaq, not a metir forecast.

Symbol: SNY
Type: Stock
Sector: Health Care
Industry: Biotechnology: Pharmaceutical Preparations
Country: Europe
Exchange: NASDAQ-GS

Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.

Key Issues

Bullish view

Dupixent surpassed €5 billion in quarterly sales for the first time, while recently launched medicines, strong sales and cost discipline supported double-digit second-quarter growth. That momentum can lessen the near-term impact of pipeline disappointments.

Bearish view

The market still pushed the shares sharply lower after the earnings beat and raised outlook because pipeline setbacks remain a strategic concern. Strong current products may not resolve longer-term growth questions.

Analyst Consensus

See all

Hold

13 analysts

$43

Current

—

Low

$55

Average

—

High

Average target implies +27.25% versus the current price.

Earnings History

BeatMissNo estimate

Peers

GSK plc American Depositary Shares (Each representing two Ordinary Shares)GSK · NYSE$51.48